More efficient clinical trials through use of scientific model-based statistical tests

被引：37

作者：

Jonsson, EN

Sheiner, LB

机构：

[1] Univ Calif San Francisco, Sch Med, Dept Lab Med, San Francisco, CA 94143 USA

[2] Uppsala Univ, Dept Pharmaceut Biosci, Div Pharmacokinet & Drug Therapy, Uppsala, Sweden

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2002年 / 72卷 / 06期

关键词：

D O I：

10.1067/mcp.2002.129307

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：603 / 614

页数：12

共 29 条

[1]

Angrist JD, 1996, J AM STAT ASSOC, V91, P444, DOI 10.2307/2291629

[2] Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].

Atkinson, AJ ;

Colburn, WA ;

DeGruttola, VG ;

DeMets, DL ;

Downing, GJ ;

Hoth, DF ;

Oates, JA ;

Peck, CC ;

Schooley, RT ;

Spilker, BA ;

Woodcock, J ;

Zeger, SL .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95

[3] Criteria for the validation of surrogate endpoints in randomized experiments [J].

Buyse, M ;

Molenberghs, G .

BIOMETRICS, 1998, 54 (03) :1014-1029

[4]

COX D. R., 2000, Theoretical Statistics

[5]

DIGGLE P, 1994, J ROY STAT SOC C, V43, P49

[6]

DIGGLE PJ, 1995, ANAL LONGITUDINAL DA

[7]

Dixon W.J., 1969, INTRO STAT ANAL

[8] MISSING DATA, IMPUTATION, AND THE BOOTSTRAP [J].

EFRON, B .

JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1994, 89 (426) :463-475

[9]

Fisher Ronald A., 1935, DESIGN EXPT

[10] Surrogate end points in clinical trials: Are we being misled? [J].

Fleming, TR ;

DeMets, DL .

ANNALS OF INTERNAL MEDICINE, 1996, 125 (07) :605-613

← 1 2 3 →